Prognostic role of E-cadherin in patients with advanced serous ovarian cancer

• Published in: Archives of gynecology and obstetrics Vol. 287; no. 6; pp. 1219 - 1224
• Main Authors: Bačić, Boris, Haller, Herman, Mrklić, Ivana, Košta, Vana, Čarić, Ana, Tomić, Snježana
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.06.2013; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - analysis; Cadherins - analysis; Endocrinology; Female; Gynecologic Oncology; Gynecology; Human Genetics; Humans; Immunohistochemistry; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Staging; Neoplasm, Residual - pathology; Neoplasms, Cystic, Mucinous, and Serous - chemistry; Neoplasms, Cystic, Mucinous, and Serous - mortality; Neoplasms, Cystic, Mucinous, and Serous - pathology; Obstetrics/Perinatology/Midwifery; Ovarian cancer; Ovarian Neoplasms - chemistry; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Prognosis; Surgery; Survival Rate; Immunohistochemistry; Prognosis; E-cadherin; Ovarian cancer
• ISSN: 0932-0067; 1432-0711
• DOI: 10.1007/s00404-012-2684-9

Purpose To analyse correlation between expression of E-cadherin and clinical and pathological features and overall survival in advanced-stage serous ovarian carcinoma. Methods The expression of E-cadherin was analysed immunohistochemically in formalin-fixed, paraffin-embedded samples from 54 patients with advanced-stage serous ovarian cancer and related to clinicopathological characteristics and patients survival. The clinicopathological characteristics included the stage according to the International Federation of Gynecology and Obstetrics (FIGO), tumour differentiation, number of mitoses per 10 high-power fields (HPF), residual tumour size, and vascular invasion. Only patients with serous ovarian cancer FIGO stages III–IV were included. Overall survival (OS) was defined as time from surgery to the last follow-up date on 01.10.2010. OS was evaluated using Kaplan–Meier method, and log-rank test was used to asses the differences between the positive and E-cadherin negative group. Multivariate analysis was completed using the Cox proportional hazard regression model. Results E-cadherin immunoreactivity was not associated with FIGO stage, tumour grade, number of mitotic figures per 10 HPF, residual tumour volume or vascular invasion. Negative E-cadherin expression significantly predicted shorter OS ( p  < 0.001). The multivariate analyses showed that negative E-cadherin ( p  < 0.001), FIGO stage ( p  = 0.012) and residual tumour size >1 cm after the initial cytoreductive surgery ( p  < 0.001) were predictors of shorter OS. Conclusion Negative E-cadherin expression like presence of residual tumour after primary cytoreductive surgery and higher FIGO stage seem to predict unfavourable clinical outcome in patients with advanced-stage serous ovarian cancer. Negative expression of E-cadherin was shown to be a significant independent predictor of poorer OS. E-cadherin as marker has prognostic value.